Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial
Publication date
2025-12
Authors
Post, Cathalijne C.B.
de Boer, Stephanie M.
Powell, Melanie E.
Mileshkin, Linda
Katsaros, Dionyssios
Bessette, Paul
Leary, Alexandra
Ottevanger, Petronella B.
McCormack, Mary
Khaw, Pearly
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
(Abstracted from Lancet Oncol 2025;26(10):1370–1381) Fifteen percent to 20% of endometrial cancer patients have a high-risk form of the disease; this classification indicates a higher risk of cancer recurrence and cancer-related death. The standard therapy for high-risk endometrial cancer is pelvic radiotherapy.
Keywords
Taverne, Obstetrics and Gynaecology
Citation
Post, C C B, de Boer, S M, Powell, M E, Mileshkin, L, Katsaros, D, Bessette, P, Leary, A, Ottevanger, P B, McCormack, M, Khaw, P, D’Amico, R, Fyles, A, Chargari, C, Kitchener, H C, Do, V, Lissoni, A, Procencher, D, Genestrie, C, Nijman, H W, Whitmarsh, K, Jürgenliemk-Schulz, I M, Feeney, A, Lutgens, L C H W, Bouma, J, Leon-Castillo, A, Nout, R A, Putter, H, Bosse, T & Creutzberg, C L 2025, 'Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) : 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial', Obstetrical and Gynecological Survey, vol. 80, no. 12, pp. 757-759. https://doi.org/10.1097/OGX.0000000000001475